AUPH
Aurinia Pharmaceuticals Inc
3.07%
$8.48 - $8.74
Feb 8th 2023 - Mar 22nd 2023
Mar, 16, 2023
Sales improving, patent safe, patent extension 203... See more
Mar, 14, 2023
That together with no competition in the field, pa... See more
No reviews available.
Mar, 16, 2023
Sales improving, patent safe, patent extension 2037, increase in insurance covering.
Mar, 14, 2023
That together with no competition in the field, patent life, IPR out of the way is a mix of cocktails that favors BO.
Mar, 10, 2023
Blockbuster drug with improving sales and long patent life
Mar, 1, 2023
$AUPH patent is safe.
Feb, 6, 2023
It was easy when you had that patent lock on you.
Feb, 6, 2023
The patent challenges are now over and IP protection is very solid.
Feb, 1, 2023
$AUPH The BBT TRX/NRX numbers are showing a significant jump, the patent challenges are over and new patents solidify the IP, the revenue outlook Peter provided is obviously very easy to beat, especially if TRX/NRX numbers continue high.
Jan, 31, 2023
Anyway, the Patent’s they filed for again Europe and US, what’s the guess for approval and think that would be a big plus on BO.
Nov, 13, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 12, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 7, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 7, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 7, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 6, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 5, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 4, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Nov, 4, 2022
Sava has a good and clean global patent until 2037 plus extensions.
Oct, 7, 2022
$ENSC 8mil mcap, just patents alone is worth 100mill ++ Product showing better results than OxyContin.